Zealand Pharma AS (ZEAL) Stock Analyst Earnings Estimates
NASDAQ:ZEAL - Nasdaq - US98920Y3045 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 41.333M 8.84% | 353.314M 754.80% | 292.567M -17.19% | 321.504M 9.89% | 668.937M 108.06% | 658.461M -1.57% | 989.302M 50.24% | 1.516B 53.25% | |
| EBITDA YoY % growth | -559.496M -21.90% | -748.479M -33.78% | -957.559M -27.93% | -1.022B -6.76% | -898.722M 12.08% | -411.57M 54.20% | -537.239M -30.53% | -715.304M -33.14% | |
| EBIT YoY % growth | -573.178M -23.66% | -791.171M -38.03% | -997.808M -26.12% | -1.015B -1.76% | -962.208M 5.23% | -658.104M 31.60% | -764.035M -16.10% | -904.757M -18.42% | |
| Operating Margin | -1,386.73% | -223.93% | -341.05% | -315.81% | -143.84% | -99.95% | -77.23% | -59.68% | |
| EPS YoY % growth | -16.22 -189.66% | -21.17 -30.51% | -22.78 -7.61% | -23.98 -5.24% | -17.94 25.19% | -13.40 25.29% | -16.45 -22.78% | -20.61 -25.24% |
All data in DKK
| Q3 / 22 | Q4 / 22 | |
|---|---|---|
| EPS Q2Q % growth | -5.69 -28.66% | -4.99 19.85% |
| Revenue Q2Q % growth | 18.36M -82.75% | 12.75M -76.40% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -221.748M -4.70% | -203.439M 29.26% |
All data in DKK
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -10.59 -60.70% | -7.40 | -3.19 | -43.17% |
| Q1 2022 Q2Q % growth | -4.95 10.73% | -6.48 | 1.53 | 23.58% |
| Q4 2021 Q2Q % growth | -6.23 33.50% | -6.21 | -0.01 | -0.20% |
| Q3 2021 Q2Q % growth | -4.42 19.97% | -6.02 | 1.60 | 26.59% |
| Q2 2021 Q2Q % growth | -6.59 -337.58% | -6.02 | -0.57 | -9.47% |
| Q1 2021 Q2Q % growth | -5.54 -16.06% | -6.04 | 0.49 | 8.16% |
| Q4 2020 Q2Q % growth | -9.36 -94.81% | -5.34 | -4.02 | -75.33% |
| Q3 2020 Q2Q % growth | -5.53 -67.44% | -5.16 | -0.37 | -7.10% |
| Q2 2020 Q2Q % growth | -1.51 63.74% | -0.83 | -0.68 | -82.52% |
| Q1 2020 Q2Q % growth | -4.78 -20.58% | -4.79 | 0.01 | 0.22% |
| Q4 2019 Q2Q % growth | -4.81 | -1.03 | -3.78 | -367.79% |
| Q3 2019 Q2Q % growth | -3.30 | -2.24 | -1.06 | -47.27% |
| Q2 2019 Q2Q % growth | -4.15 | -2.61 | -1.55 | -59.29% |
| Q1 2019 Q2Q % growth | -3.96 | -4.01 | 0.05 | 1.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | 28.374M -22.36% | 54.444M | -26.07M | -47.88% |
| Q1 2022 Q2Q % growth | 15.077M 164.32% | 64.928M | -49.851M | -76.78% |
| Q4 2021 Q2Q % growth | 54.015M -14.74% | 82.777M | -28.762M | -34.75% |
| Q3 2021 Q2Q % growth | 106.407M 88.24% | 71.741M | 34.666M | 48.32% |
| Q2 2021 Q2Q % growth | 36.547M -83.46% | 63.757M | -27.21M | -42.68% |
| Q1 2021 Q2Q % growth | 5.704M -54.06% | 63.276M | -57.572M | -90.99% |
| Q4 2020 Q2Q % growth | 63.356M 451.26% | 108.015M | -44.659M | -41.35% |
| Q3 2020 Q2Q % growth | 56.526M 469.70% | 78.799M | -22.273M | -28.27% |
| Q2 2020 Q2Q % growth | 221.016M 1,009.63% | 204.986M | 16.03M | 7.82% |
| Q1 2020 Q2Q % growth | 12.416M | 16.32M | -3.904M | -23.92% |
| Q4 2019 Q2Q % growth | 11.493M | 159.375M | -147.882M | -92.79% |
| Q3 2019 Q2Q % growth | 9.922M | 32.012M | -22.09M | -69.01% |
| Q2 2019 Q2Q % growth | 19.918M | 12.75M | 7.168M | 56.22% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |